Phosphorylated CXCR4 Expression Has a Positive Prognostic Impact in Colorectal Cancer

Overview

Journal Cell Oncol (Dordr)

Publisher Springer

Date 2017 Sep 23

PMID 28936810

Citations 7

Authors

B Weixler

F Renetseder

I Facile

N Tosti

E Cremonesi

A Tampakis

T Delko

S Eppenberger-Castori

A Tzankov

G Iezzi

C Kettelhack

S D Soysal

U von Holzen

G C Spagnoli

L Terracciano

L Tornillo

Raoul A Droeser

S Daster

Affiliations

Soon will be listed here.

Abstract

Background: The CXCL12-CXCR4 chemokine axis plays an important role in cell trafficking as well as in tumor progression. In colorectal cancer (CRC), the chemokine receptor CXCR4 has been shown to be an unfavorable prognostic factor in some studies, however, the role of its activated (phosphorylated) form, pCXCR4, has not yet been evaluated. Here, we aimed to investigate the prognostic value of CXCR4 and pCXCR4 in a large cohort of CRC patients.

Patients And Methods: A tissue microarray (TMA) of 684 patient specimens of primary CRCs was analyzed by immunohistochemistry (IHC) for the expression of CXCR4 and pCXCR4 by tumor cells and tumor-infiltrating immune cells (TICs).

Results: The combined high expression of CXCR4 and pCXCR4 showed a favorable 5-year overall survival rate (68%; 95%CI = 59-76%) compared to tumors showing a high expression of CXCR4 only (48%; 95%CI = 41-54%). High expression of pCXCR4 was significantly associated with a favorable prognosis in a test and validation group (p = 0.015 and p = 0.0001). Moreover, we found that CRCs with a high density of pCXCR4+ tumor-infiltrating immune cells (TICs) also showed a favorable prognosis in a test and validation group (p = 0.054 and p = 0.004). Univariate Cox regression analysis for TICs revealed that a high density of pCXCR4+ TICs was a favorable prognostic marker for overall survival (HR = 0.97,95%CI = 0.96-1.00; p = 0.01). In multivariate Cox regression survival analyses a high expression of pCXCR4 in tumor cells lost its association with a better overall survival (HR = 0.99; 95%CI = 0.99-1.00, p = 0.098).

Conclusion: Our results show that high densities of CXCR4 and pCXCR4 positive TICs are favorable prognostic factors in CRC.

Citing Articles

Muscarinic Acetylcholine Receptor M3 Expression and Survival in Human Colorectal Carcinoma-An Unexpected Correlation to Guide Future Treatment?.

Lobbes L, Schutze M, Droeser R, Arndt M, Pozios I, Lauscher J Int J Mol Sci. 2023; 24(9).

PMID: 37175905 PMC: 10179005. DOI: 10.3390/ijms24098198.

The prognostic significance of CXCR4 and SDF-1 in differentiated thyroid cancer depends on CD8+ density.

Wilhelm A, Lemmenmeier I, Lalos A, Posabella A, Kancherla V, Piscuoglio S BMC Endocr Disord. 2022; 22(1):292.

PMID: 36419107 PMC: 9686066. DOI: 10.1186/s12902-022-01204-2.

The clinicopathological and prognostic value of CXCR4 expression in patients with lung cancer: a meta-analysis.

Qiu L, Xu Y, Xu H, Yu B BMC Cancer. 2022; 22(1):681.

PMID: 35729596 PMC: 9210617. DOI: 10.1186/s12885-022-09756-1.

High ratio of pCXCR4/CXCR4 tumor infiltrating immune cells in primary high grade ovarian cancer is indicative for response to chemotherapy.

Walther F, Berther J, Lalos A, Ramser M, Eichelberger S, Mechera R BMC Cancer. 2022; 22(1):376.

PMID: 35397601 PMC: 8994232. DOI: 10.1186/s12885-022-09374-x.

Prognostic Significance of CXCR4 in Colorectal Cancer: An Updated Meta-Analysis and Critical Appraisal.

Ottaiano A, Santorsola M, Prete P, Perri F, Scala S, Caraglia M Cancers (Basel). 2021; 13(13).

PMID: 34209026 PMC: 8269109. DOI: 10.3390/cancers13133284.

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Kim J, Takeuchi H, Lam S, Turner R, Wang H, Kuo C . Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol. 2005; 23(12):2744-53. DOI: 10.1200/JCO.2005.07.078. View

Phillips R, Burdick M, Lutz M, Belperio J, Keane M, Strieter R . The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med. 2003; 167(12):1676-86. DOI: 10.1164/rccm.200301-071OC. View

Pages F, Galon J, Dieu-Nosjean M, Tartour E, Sautes-Fridman C, Fridman W . Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2009; 29(8):1093-102. DOI: 10.1038/onc.2009.416. View

Lim K, Hyun Y, Lambert-Emo K, Capece T, Bae S, Miller R . Neutrophil trails guide influenza-specific CD8⁺ T cells in the airways. Science. 2015; 349(6252):aaa4352. PMC: 4809646. DOI: 10.1126/science.aaa4352. View

Kim J, Mori T, Chen S, Amersi F, Martinez S, Kuo C . Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg. 2006; 244(1):113-20. PMC: 1570598. DOI: 10.1097/01.sla.0000217690.65909.9c. View

Xu F, Wang F, Di M, Huang Q, Wang M, Hu H . Classification based on the combination of molecular and pathologic predictors is superior to molecular classification on prognosis in colorectal carcinoma. Clin Cancer Res. 2007; 13(17):5082-8. DOI: 10.1158/1078-0432.CCR-07-0597. View

Brenner H, Kloor M, Pox C . Colorectal cancer. Lancet. 2013; 383(9927):1490-1502. DOI: 10.1016/S0140-6736(13)61649-9. View

Hampel H, Stephens J, Pukkala E, Sankila R, Aaltonen L, Mecklin J . Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology. 2005; 129(2):415-21. DOI: 10.1016/j.gastro.2005.05.011. View

10.

Sterlacci W, Saker S, Huber B, Fiegl M, Tzankov A . Expression of the CXCR4 ligand SDF-1/CXCL12 is prognostically important for adenocarcinoma and large cell carcinoma of the lung. Virchows Arch. 2016; 468(4):463-71. DOI: 10.1007/s00428-015-1900-y. View

11.

Schimanski C, Schwald S, Simiantonaki N, Jayasinghe C, Gonner U, Wilsberg V . Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res. 2005; 11(5):1743-50. DOI: 10.1158/1078-0432.CCR-04-1195. View

12.

Lech G, Slotwinski R, Slodkowski M, Krasnodebski I . Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances. World J Gastroenterol. 2016; 22(5):1745-55. PMC: 4724606. DOI: 10.3748/wjg.v22.i5.1745. View

13.

Spano J, Andre F, Morat L, Sabatier L, Besse B, Combadiere C . Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncol. 2004; 15(4):613-7. DOI: 10.1093/annonc/mdh136. View

14.

Lombardi L, Tavano F, Morelli F, Latiano T, Di Sebastiano P, Maiello E . Chemokine receptor CXCR4: role in gastrointestinal cancer. Crit Rev Oncol Hematol. 2013; 88(3):696-705. DOI: 10.1016/j.critrevonc.2013.08.005. View

15.

Coussens L, Werb Z . Inflammation and cancer. Nature. 2002; 420(6917):860-7. PMC: 2803035. DOI: 10.1038/nature01322. View

16.

Schimanski C, Galle P, Moehler M . Chemokine receptor CXCR4-prognostic factor for gastrointestinal tumors. World J Gastroenterol. 2008; 14(30):4721-4. PMC: 2739331. DOI: 10.3748/wjg.14.4721. View

17.

Thelen M . Dancing to the tune of chemokines. Nat Immunol. 2001; 2(2):129-34. DOI: 10.1038/84224. View

18.

Wendt M, Johanesen P, Kang-Decker N, Binion D, Shah V, Dwinell M . Silencing of epithelial CXCL12 expression by DNA hypermethylation promotes colonic carcinoma metastasis. Oncogene. 2006; 25(36):4986-97. PMC: 4610155. DOI: 10.1038/sj.onc.1209505. View

19.

Roy I, Zimmerman N, Mackinnon A, Tsai S, Evans D, Dwinell M . CXCL12 chemokine expression suppresses human pancreatic cancer growth and metastasis. PLoS One. 2014; 9(3):e90400. PMC: 3942415. DOI: 10.1371/journal.pone.0090400. View

20.

Konoplev S, Jorgensen J, Thomas D, Lin E, Burger J, Kantarjian H . Phosphorylated CXCR4 is associated with poor survival in adults with B-acute lymphoblastic leukemia. Cancer. 2011; 117(20):4689-95. DOI: 10.1002/cncr.26113. View